Novartis’ AveXis unit has said European regulators have approved its Zolgensma (onasemnogene abeparvovec) gene therapy for the rare childhood wasting disease spinal muscular atrophy (SMA), and ...
Mike Fraser, general manager EMEA at AveXis, said: “All gene therapies are required to go through the benefit assessment process (AMNOG) in Germany and this will be ongoing in the coming months ...
Meanwhile, in Durham, co-founder Jeffs will lead a team focused on development and manufacturing. It will include Britt Petty, AveXis’ former head of global manufacturing and Melissa Rhodes, former ...
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback